P&G cancels collaboration on Aryx drug despite its passing safety study(0)
Aryx says its drug candidate ATI-7505 designed to treat chronic constipation and abdominal pain passed “an important cardiac safety study” conducted under a collaboration agreement with Procter & Gamble Pharmaceuticals, according to one of the press releases the company put out Wednesday.
Unfortunately for Aryx, a second release it put out disclosed that P&G has chosen to use a “one-time thirty day cancellation option” to withdraw from that same agreement. Read the rest of this entry »
Subscribe via RSS all feeds